RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Exuma Biopharma, a German-China company, announced early positive results from a China Phase I trial of two CAR-T candidates in patients with solid tumor cancers. The trial, which enrolled subjects with advanced renal cell carcinomas, tested two conditionally active CAR-T products, CCT301-38 (AXL) and CCT301-59 (ROR2). Exuma said the products are the first CABs to be tested in humans. Both CABs turn the growth inhibitory acidic tumor microenvironment into one activating signal, followed by the activation of the target antigen (AXL or ROR2).
Source: China Biotoday
